Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CHKA | P35790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20574823 | 0.92 | LMNA (0.35) | HDAC4POLBMAPK1SMN1; SMN2CHRNA7 | |
| SCHEMBL20575524 | 0.88 | ECE2 (0.30) | — | |
| SCHEMBL20575568 | 0.87 | POLB (0.34) | HDAC4POLBMAPK1SMN1; SMN2CHRNA7 | |
| SCHEMBL20575625 | 0.84 | PDE4B (0.38) | HDAC4POLBMAPK1SMN1; SMN2CHRNA7 | |
| SCHEMBL20575476 | 0.84 | LMNA (0.34) | HDAC4POLBMAPK1SMN1; SMN2CHRNA7 | |
| SCHEMBL20576465 | 0.84 | POLB (0.35) | HDAC4POLBMAPK1SMN1; SMN2CHRNA7 | |
| SCHEMBL20575600 | 0.81 | CHRNA7 (0.37) | POLBMAPK1SMN1; SMN2CHRNA7SLC6A2 | |
| SCHEMBL20575587 | 0.81 | SLC6A2 (0.34) | SMN1; SMN2CHRNA7SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL20575593 | 0.81 | IDO1 (0.38) | POLBMAPK1SMN1; SMN2CHRNA7SLC6A2 | |
| SCHEMBL20575632 | 0.79 | FASN (0.35) | CHRNA7SLC6A2SLC6A4SLC6A3KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10696693-B2 | Fused imidazole derivatives as TGF-beta inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-20180346487-A1 | Fused Imidazole Derivatives as TGF-Beta Inhibitors | MIDCAP FINANCIAL TRUST | 2018-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696693-B2 | Fused imidazole derivatives as TGF-beta inhibitors | TGFBR1, TGFBR2, SMAD3 | HDAC4 371/4885POLB 2233/4885MAPK1 320/4885 |
| US-20180346487-A1 | Fused Imidazole Derivatives as TGF-Beta Inhibitors | TGFBR1, TGFBR2, SMAD3 | HDAC4 371/4885POLB 2233/4885MAPK1 320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.